News

Personalis, Inc. (PSNL) ctDNA Test Predicts TNBC Relapse Risk Post-Therapy
Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...
Le Lézard3d
New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse
Personalis, Inc. , a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of ...
ascopubs.org4d
EGFR, MUC-1 and PD-L1 expressions in cases with triple negative breast cancer (TNBC).
This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting I. This abstract does not include a full text component.
pharmaphorum4d
ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC
Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...
MedPage Today5d
First-Line Keytruda-Trodelvy Boosts PFS in Triple-Negative Breast Cancer
CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...
BlackDoctor6d
3 Ways To Fight Triple-Negative Breast Cancer in the Kitchen
It takes strength, courage, and pure grit to undergo the journey of cancer treatment. Triple-negative breast cancer is the most challenging opponent for women who fight breast cancer. African-American ...